Bodem Barbara W. 4

What Happened Barbara W. Bodem, a director of BioMarin Pharmaceutical Inc. (BMRN), was granted 7,490 restricted stock units (RSUs) on June 2, 2026. The reported acquisition shows a $0 per-share price because these are equity awards (transaction code A), not open-market purchases or sales. Total cash value is not reported on the Form 4; the award represents compensation rather than a purchase.

Key Details

• Transaction date: June 2, 2026 (reported on Form 4 filed June 4, 2026).
• Transaction type/code: Grant/Award (A); 7,490 RSUs granted.
• Price: $0.00 per share (price not applicable for RSU grants).
• Footnote: F1 — "Restricted stock units granted on June 2, 2026. Price not applicable."
• Shares owned after transaction: Not specified in the provided filing data.
• Timeliness: Form 4 filed June 4, 2026 (appears to be within the normal reporting window).

Context RSUs are typically compensation that vest over time or upon achievement of conditions; they are not an immediate purchase or sale and do not by themselves signal a buy/sell decision. For retail investors, awards to directors are common as part of governance/compensation practices and should be viewed as compensation disclosures rather than direct endorsements of near-term stock performance.